ArticleNature2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
22.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 135 citations in OpenAlex.
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Article
- Unraveling the lexicon of complex mutational phenomena in human cancers.Nature cancer · 2026Review
- Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer.Science advances · 2026Article
- Replication stress in cancer: origins, consequences and therapeutic opportunities.Nature reviews. Cancer · 2026Review
- Dissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses.Molecular therapy. Oncology · 2026Article
- Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines.Precision clinical medicine · 2026Review
- Intratumoral Mycobacterium abscessus promotes cytidine deaminase mutagenesis in non-small cell lung cancer.Signal transduction and targeted therapy · 2026Article
- Distinct repair processes produce APOBEC-induced deletions, tandem substitutions, and complex mutations in yeast and human cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Evolution ofInternational journal of molecular sciences · 2026Review
- Squamous-state excursions activate APOBEC3A in cancer.bioRxiv : the preprint server for biology · 2026Article
- Chemiluminescent Deoxyribozyme Sensors for DNA-Editing Enzymes.ACS chemical biology · 2026Article
- Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases.Cancer · 2026Review
- UNG-RPA interaction governs the choice between high-fidelity and mutagenic uracil repair.Nucleic acids research · 2026Article
- Stress-responsive membrane proteins as execution nodes of tumor cell adaptation to microenvironmental stress.Oncogene · 2026Review
- Review
- RNA-templated diversity generation via reverse transcription and homologous recombination: an evolutionary hypothesis.Theory in biosciences = Theorie in den Biowissenschaften · 2026Article
- Mathematical modeling of ribosome competition informs testable treatment strategies for drug-tolerant cancer persister cells.iScience · 2026Article
- Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance.The Journal of clinical investigation · 2026Article
- Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans.Biochimica et biophysica acta. Reviews on cancer · 2026Review
44 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
41 authors at 6 institutions in 2 countries.
Hideko IsozakiMassachusetts General Hospital Cancer Center, Boston, MA, USA. hisozaki@mgh.harvard.edu.ORCID 0000-0003-0124-996X
Ramin SakhtemaniMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0001-5342-9415
Ammal AbbasiMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Naveed NikpourMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Marcello StanzioneMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Sunwoo OhDepartment of Biological Chemistry, Center for Epigenetics and Metabolism, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, CA, USA.ORCID 0000-0001-9205-4660
Adam LangenbucherMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Susanna MonroeMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0002-4775-4323
Wenjia SuMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Heidie Frisco CabanosMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Faria M SiddiquiMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Nicole PhanMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Pégah JaliliDepartment of Biological Chemistry, Center for Epigenetics and Metabolism, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, CA, USA.
Daria TimoninaMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Samantha BiltonMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Maria Gomez-CaraballoMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Hannah L ArchibaldMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Varuna NangiaMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0001-5142-4653
Kristin DionneMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Amanda RileyMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0002-5720-3269
Matthew LawlorMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Mandeep Kaur BanwaitMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Rosemary G CobbMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Lee ZouMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0003-3094-1058
Nicholas J DysonMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Christopher J OttMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0001-6142-7241
Cyril BenesMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0002-8751-9707
Gad GetzMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Chang S ChanDepartment of Medicine, Rutgers Robert Wood Johnson Medical School and Center for Systems and Computational Biology, Rutgers Cancer Institute, New Brunswick, NJ, USA.ORCID 0000-0001-9897-4759
Alice T ShawMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0001-6337-1093
Justin F GainorMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Jessica J LinMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0001-7373-3916
Lecia V SequistMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0002-8965-6991
Zofia PiotrowskaMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Beow Y YeapMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Jeffrey A EngelmanMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Jake June-Koo LeeDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1348-4094
Yosef E MaruvkaFaculty of Biotechnology and Food Engineering, Lorey Loki Center for Life Science and Engineering, Technion, Haifa, Israel.
Rémi BuissonDepartment of Biological Chemistry, Center for Epigenetics and Metabolism, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, CA, USA.ORCID 0000-0002-7196-8209
Michael S Lawrence *Massachusetts General Hospital Cancer Center, Boston, MA, USA. mslawrence@mgh.harvard.edu.ORCID 0000-0002-1307-459X
Aaron N Hata *Massachusetts General Hospital Cancer Center, Boston, MA, USA. ahata@mgh.harvard.edu.ORCID 0000-0002-6127-318X
Massachusetts General Hospital · USHarvard University · USBroad Institute · USUniversity of California, Irvine · USRutgers, The State University of New Jersey · USTechnion – Israel Institute of Technology · IL
Funding
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9MProject 3P50CA265826 · NCI · DANA-FARBER CANCER INST · PI Daniel Botelho Costa · 2022 to 2026
$13.7MThe Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted TherapiesR01CA137008 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, ZOFIA PIOTROWSKA · 2009 to 2026
$5.7MOvercoming Resistance Mechanisms to Anaplastic Lymphoma Kinase InhibitorsR01CA164273 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, Jessica Jiyeong Lin · 2012 to 2026
$5.5MUsing patient-derived models to understand drug responses in SCLCU01CA220323 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DYSON, NICHOLAS J · 2018 to 2022
$3.1MMechanisms driving lung cancer evolution during targeted kinase inhibitor treatmentR01CA249291 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HATA, AARON N · 2020 to 2024
$2.6MMolecular Mechanisms of APOBEC-Induced Mutagenesis in CancerR37CA252081 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2021 to 2026
$2.5MEvolution of resistance of EGFR mutant non-small cell lung cancerK08CA197389 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HATA, AARON N · 2016 to 2020
$896kNCI NIH HHS K08 CA197389NCI NIH HHS P30 CA062203NCI NIH HHS P50 CA265826NCI NIH HHS R01 CA137008NCI NIH HHS R01 CA164273NCI NIH HHS R01 CA249291NCI NIH HHS R37 CA252081NCI NIH HHS U01 CA220323
Abstract
Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified
Indexed as
Cytidine DeaminaseLung NeoplasmsDNA Breaks, Double-StrandedDrug Resistance, NeoplasmGenomic InstabilityHumansMolecular Targeted TherapyMutationProteinsAPOBEC3A protein, humanCytidine DeaminaseProteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.